PA1-915

antibody from Invitrogen Antibodies

Targeting: ATP2B2 PMCA2

Provider product page for PA1-915

Western blot

ELISA

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [32]
Comments [0]
Validations
Other assay [31]

Submit

Product number: PA1-915 - Provider product page
Provider: Invitrogen Antibodies
Product name: PMCA2 ATPase Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: PA1-915 detects calcium pump of the plasma membrane 2 (PMCA2 ATPase) from human and rat and porcine tissues and cells. PA1-915 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~127 kDa protein and an ~133 kDa protein representing PMCA2a and PMCA2b ATPase, respectively, from rat brain microsomal fractions. PA1-915 immunizing peptide corresponds to amino acid residues 5-19 from human PMCA2 ATPase protein. This sequence is completely conserved between human and rat PMCA2 ATPase.
Reactivity: Human, Rat, Porcine
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

ATP2B2 protein structure - PA1-915 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 4. Expression and immunolocalization of recombinant PMCA2 w/a pumps in CHO cells. A , Western blotting analysis is shown. The band of ~130 kDa corresponds to PMCA2, and the band of ~42 kDa corresponds to beta-actin. B , densitometric analysis of relative expression of wild type PMCA2 w/a and PMCA2 w/a harboring the Tommy mutation is shown. The amounts of pump protein were as normalized for beta-actin. C , immunolocalization of wild type ( left ) and mutant (right ) PMCA2 w/a in transiently transfected CHO cells is shown. The interaction with the 2N antibody was probed by the AlexaFluor488-conjugated secondary antibody. D , fluorescence levels in the plasma membrane is quantified as described under ""Experimental Procedures."" Bars represent S.D.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 7. PMCA2 immunolabeling in neonatal utricle. Confocal imaging immunoassays of PMCA2 (stained by Alexa 488 conjugated, green ) in P7 utricle cultures from wild type, heterozygous, and homozygous Tommy mice (for details see ""Experimental Procedures""). Membranes ( red ) are stained by FM4-64FX, whereas nuclei ( blue ) are stained by DAPI. Scale bar , 10 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 8. PMCA2 immunolabeling in P60 cochlea whole mounts. Horizontal sections (orthogonal to the modiolus) of cochlea whole mounts from P60 wild type ( left column ) and homozygous ( right column ) Tommy mice are shown. Images from apical, medial, and basal regions are obtained by maximal back-projection of 20 confocal optical sections from a 2-mum step z-stack of wild type and homozygous Tommy mice. PMCA2 expression was probed by a PMCA2 selective antibody (Alexa 488 conjugated, green ), and nuclei were stained with DAPI ( blue ). Scale bar , 15 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 9. PMCA2 immunolabeling in basal cochlear transversal sections (parallel to the modiolus) of P60 Tommy mice. Images were obtained by maximal back-projection of 2-6 confocal optical sections from a 1-mum step z-stack of wild type ( top panel ) and homozygous ( bottom panel ) Tommy mice. Actin filaments were stained with phalloidin (Texas Red-conjugated, red ) and nuclei with DAPI ( blue ). Scale bar , 15 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 PMCA2 expression in human breast tissue with lactational change and in breast cancer tissues. ( A - D ) Human breast sections with lactational change; ( A ) hematoxylin and eosin staining; ( B ) beta-casein staining showing accumulation of milk protein in the lumen; ( C , D ) PMCA2 staining showing PMCA2 accumulation on apical membranes of epithelial cells with lactational change. ( E - G ) Examples of PMCA2 staining in breast cancer tissues; ( E ) PMCA2-negative cancer, showing light diffuse brown background staining, ( F ) More intense PMCA2 staining in the cytoplasm with no plasma membrane localization, these were also defined as PMCA2-negative cancer in our analysis, ( G ) Clear PMCA2 staining on the plasma membrane, these were defined as PMCA2-positive cancers (PMCA2-PM+) given the localization of the PMCA2 plasma membrane Ca 2+ pump on the plasma membrane of these breast cancer cells. Original magnification 3x ( A-C ), 20x ( D ), 5x main images and 20x for insert ( E - G ).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1. PMCA2 regulates transmitter release in the MNTB. A and B : immunohistochemical labeling for MAP2 and PMCA2 in the MNTB ( A ) and in an individual MNTB neuron ( B ). A cross section through the calyx is marked ""calyx."" Arrows show where PMCA2 appears to be localized presynaptically in the outer membrane of the calyx. C : voltage-clamp recordings from postsynaptic MNTB neurons in acute brain slices show a higher frequency of miniature excitatory postsynaptic currents (mEPSCs) in the MNTB of dfw 2J / dfw 2J mice compared with wild type (WT). D : calyceal EPSCs evoked by midline stimulation are larger in dfw 2J / dfw 2J mice compared with WT. Stimulus artifacts have been deleted for clarity. WT data include 7 medial cells, 3 lateral cells, and 8 cells with no information about location in the MNTB. dfw 2J / dfw 2J data include 7 medial cells, 6 lateral cells, and 4 cells with no information about location in the MNTB (see also Fig. 4 C ). E and F : in vivo single-unit recordings of MNTB neurons measured higher spontaneous firing rates ( E ) and shorter synaptic delays ( F ) in dfw 2J / dfw 2J mice compared with WT. *** P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig 3 HER2 regulates intracellular calcium concentration in SKBR3 cells. A) PMCA2 levels in control versus HER2KD-SKBR3 cells as assessed by immunoblot. B) Intracellular calcium measurements in HER2KD-SKBR3 cells relative to control. Numbers indicate the mean calcium concentrations estimated by FURA2 measurements. Each bar represents the mean +- SEM of 3 separate experiments. Asterisk denotes statistically significant difference. C) Expression of a NFAT-luciferase indicator construct in control SKBR3 cells, HER2KD-SKBR3 cells and PMCA2KD-SKBR3 cells. Each bar represents the mean +- SEM of 3 separate experiments. Asterisks denote statistically significant differences. D) Con-focal images of immunofluorescence for NFATc1 (red) or DAPI (blue) in control (top row), HER2KD-SKBR3 (middle row) or PMCA2KD-SKBR3 (bottom row) cells. Scale bars represent 10mum. E) Apoptosis as assessed by TUNEL assay in HER2KD-SKBR3 cells relative to controls exposed to differing concentrations of extracellular calcium +- ionomycin. Each bar represents the mean +- SEM of 3 separate experiments. F) Con-focal images of immunofluorescence for NFATc1 (red) or DAPI (blue) in control (top row), HER2KD-SKBR3 (middle row) or PMCA2KD-SKBR3 (bottom row) cells treated with cyclosporine A to block calcineurin activity. Scale bars represent 10mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2. A, The genomic organization of the Atp2b2 (PMCA2) gene at splice site A is illustrated with the alternatively spliced variants PMCA2w and PMCA2z shown below. RT-PCR was performed with primers (represented by arrows ) flanking the splice site. B, RT-PCR was performed on RNA from mammary glands of mice at the developmental stages noted in the figure. Mouse brain RNA served as a control for the PMCA2z splice variant (the brain sample was run on a different gel). PCR products were of the predicted sizes for either the w splice variant (377 bp) or the PMCA2z splice variant (244 bp), but PCR products were sequenced to confirm their identity. Throughout postnatal development, the mouse mammary gland expresses only the PMCA2w variant of splice site A. C and D, Immunofluorescent staining for PMCA2 in mammary tissue from a lactating mouse (d 12) demonstrated that it was located at the apical plasma membrane. E, An electron micrograph of lactating mammary tissue stained for PMCA2 using immunoperoxidase techniques confirmed the apical membrane localization. There was no PMCA2 staining in secretory vesicles or other intracellular compartments.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3. A, QRT-PCR demonstrates a progressive reduction in the expression of the PMCA2 gene ( Atp2b2 ) in the mammary glands of dfw-2J/+ mice and dfw-2J/dfw-2J mice compared with wild-type BALB/c mice. PMCA2 mRNA levels were reduced by 50% in Dfw-2J/+ glands and by 85% in dfw-2J/dfw-2J glands. B, In contrast, PMCA2 mRNA levels in mice with the dfw mutation (dfw/+ and dfw/dfw) were not different from those in control C3H mice. C, Western blotting for PMCA2 in the plasma membrane fraction of lactating mouse mammary glands revealed abundant PMCA2 in BALB/c mice (lanes 1 and 2), reduced PMCA2 in dfw-2J/+ mice (lanes 3 and 4), and no PMCA2 in dfw-2J/dfw-2J mice (lanes 5 and 6). D, PMCA2 protein levels were similar in C3H (lanes 1 and 2), dfw/+ (lanes 3 and 4), and dfw/dfw (lanes 5 and 6) mice. E and F, Quantitation of PMCA2 protein normalized to beta-actin protein levels in blots from C and D. Protein levels generally paralleled mRNA levels, with the exception that PMCA2 mRNA was detectable in dfw-2J/dfw-2J mice, but PMCA2 protein was not. An asterisk denotes statistical significance.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6. A, PMCA2 mRNA expression measured by QRT-PCR in EpH4 mouse MECs exposed to varying levels of extracellular calcium concentrations. Increasing doses of calcium or gadolinium do not increase PMCA2 mRNA expression. B, Western analysis of PMCA2 protein in EpH4 cells incubated overnight in 0.1, 1, or 10 m m calcium or 0.1 m m calcium with 100 m m gadolinium. The calcium concentration and gadolinium treatment had no effect on the amount of PMCA2 protein or its electrophoretic mobility. C, RT-PCR analysis of PMCA2 splice site A in brain (lane 1), primary mouse MECs (MMEC, lane 2), and EpH4 cells incubated in media containing 0.1 (lane 3), 1 (lane 4), or 10 (lane 5) m m calcium reveals that the PMCA2w variant is expressed in MECs, regardless of the calcium concentration. The samples were all run on the same gel, and the space between lanes 2 and 3 is where intervening lanes were removed from the image. D, Immunofluorescent staining for PMCA2 in EpH4 cells incubated for 3 h in media containing 0.1 or 1 m m calcium. The pattern of PMCA2 staining is consistent with plasma membrane localization and is unchanged at 0.1 vs . 1 m m extracellular calcium.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5. MAL2 and lipid rafts maintain interactions between HER2 and PMCA2 required to maintain low calcium concentrations at the plasma membrane (A) Live cell confocal images in SKBR3 cells expressing LCK-GCaMP at physiologic calcium (control) or treated with 10 mM extracellular calcium + 10 muM ionomycin. (B) Live cell confocal images in control and MAL2KD_SKBR3 cells expressing LCK-GCaMP. (C) Live cell confocal images in control and MbetaCD-treated SKBR3 cells expressing LCK-GCaM. (D) PMCA2 mRNA expression in control, MAL2KD-treated, or MbetaCD-treated SKBR3 cells as assessed by quantitative RT-PCR (n = 3). (E) Western blot analysis of PMCA2 protein levels in control, MAL2KD-treated, or MbetaCD-treated SKBR3 cells. (F) PLA with immunofluorescence for phalloidin in HER2 and PMCA2 in control (top row), MAL2KD-treated (middle row), and MbetaCD-treated (bottom row) SKBR3 cells. Scale bars represent 10 mum. (G) PLA for HER2 and GFP-PMCA2 with immunofluorescence for GFP-labeled PMCA2 and actin (phalloidin) in control (top row), MAL2KD-treated (middle row), and MbetaCD-treated (bottom row) SKBR3 cells. (H) Quantitation of PLA experiment from (F) and (G) by measuring the fluorescent intensity of amplified PLA reactions at the plasma membrane. (I) SIM imaging showing HER2- and GFP-labeled PMCA2 in control, MAL2KD-treated, and MbetaCD-treated SKBR3 cells. Scale bars represent 10 mum. (J) Apoptosis, as assessed by TUNEL assay, in MAL2KD cells relative to controls exposed to 5 mM cal

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. Enhanced interactions between HER2 and MAL2, Ezrin, NHERF1, and PMCA2 in trastuzumab-resistant SKBR3 cells (A) Immunofluorescence staining for cholera toxin B (lipid rafts) in control and trastuzumab-resistant SKBR3 cells. Scale bars represent 10 mum. (B) Immunofluorescence staining for HER2 and MAL2 in control and trastuzumab-resistant SKBR3 cells. Scale bars represent 10 mum. (C) PLA for HER2 and MAL2 in control and trastuzumab-resistant SKBR3 cells also stained for phalloidin. Scale bars represent 10 mum. (D-F) Quantitative results from immunoprecipitation coupled with data-independent acquisition mass spectrometry (DIA-MS) in control and trastuzumab-resistant SKBR3 cells. (D) The DIA-MS Intensity (log 2 ) of HER2 and MAL2 proteins from control and trastuzumab-resistant SKBR3 cells. (E) The DIA-MS Intensity (log 2 ) for all the peptide precursor signals of HER2 in control and resistant cells. (F) The DIA-MS peak groups visualized for quantifying HER2 (VLGSGAFGTVYK) and MAL2 (VTLPAGPDILR). Peaks above and below the middle line denote the MS2 and MS1 ion traces in DIA-MS. (G) MAL2, Ezrin, and NHERF1 mRNA expression in control and trastuzumab-resistant SKBR3 cells as assessed by quantitative RT-PCR (n = 3). (H) PLA for HER2 with Ezrin (left), NHERF1 (middle), and PMCA2 (right) in control and trastuzumab-resistant SKBR3 cells also stained for phalloidin. Boxed portions are amplified at right with co-registration of PLA signal and immunofluorescence for actin (phalloi

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Expression of PMCA isoforms in multiple pancreatic cell lines. ( A ) Representative Western immunoblot showing the relative protein expression of total/pan-PMCA and PMCA isoform 1-4 in pancreatic cancer (MIA PaCa-2 and PANC-1) and non-malignant pancreatic cells (human pancreatic ductal epithelial (HPDE) and human pancreatic stellate cells (hPSC)). Mouse brain lysate was used as a positive control for PMCA expressions and beta-Actin was used as a protein loading control. ( B ) PMCA4 protein expression in each cell line was quantified from Western blot bands and normalized to beta-Actin housekeeping protein. ( C ) The relative expressions of ATP2B1-4 (PMCA1-4 mRNA) in each cell line were quantified by RT-qPCR. Data are expressed as relative mRNA expression normalized to corresponding S18 rRNA controls (2 -DeltaCtau ). Statistical comparisons were made using the Kruskal-Wallis test with Dunn's multiple comparison test and two-way analysis of variance (ANOVA) with Dunnett's multiple comparison test. Data are expressed as mean +- SEM. (n = 4-5, 4 replicates per treatment condition). * represents statistical significance where p < 0.05.